<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01771978</url>
  </required_header>
  <id_info>
    <org_study_id>2276</org_study_id>
    <nct_id>NCT01771978</nct_id>
  </id_info>
  <brief_title>Ischaemia-réperfusion During the Coronary Surgery With Beating Heart</brief_title>
  <official_title>Effects of Diltiazem and/or N-Acétylcystéine Versus Placebo on hémodynamiques and Biological Repercussions of the Ischaemia-réperfusion During the Coronary Surgery With Beating Heart</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Less oxidative stress occurs during off-pump than on-pump coronary artery bypass graft (CABG)
      surgery but warm ischaemia-reperfusion injury may occur following transient coronary artery
      clamping. The aim of this study was to compare the preventive effects of diltiazem and
      N-acetylcysteine (NAC), alone or in combination, on biomarkers of myocardial damage and
      oxidative stress during off-pump CABG surgery.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2002</start_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduce the percentage 40% of patients operated on a beating heart to 10% as a result of treatment with diltiazem and N-acetylcysteine</measure>
    <time_frame>during ischaemia-reperfusion</time_frame>
    <description>Choosing as main biological variable rate cTnI cardiospecific, above the threshold of detection (0.3 mcg / L) in 40% of patients operated on a beating heart hoping to reduce this percentage to 10% as a result of treatment with diltiazem and N-acetylcysteine</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Ischaemia-reperfusion Injury</condition>
  <arm_group>
    <arm_group_label>Arm1: control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Received 250 ml of a 5% dextrose solution as placebo drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: diltiazem group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received a 100 µg/kg bolus followed by a 0.3 µg/kg infusion diluted in 250 ml of 5% dextrose solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: acetylcystein group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received 150 mg/kg acetylcystein diluted in 250 ml of 5% dextrose solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4: diltiazem and acetylcystein group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received a combination of drug :
bolus diltiazem 100 µg/kg followed by a 0.3 µg/kg infusion diluted in 125 ml of a 5% dextrose solution and 150 mg/kg acetylcystein diluted in 125 ml of 5% dextrose solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Received 250 ml of a 5% dextrose solution as placebo</description>
    <arm_group_label>Arm1: control group</arm_group_label>
    <other_name>placebo group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diltiazem</intervention_name>
    <description>Received a 100 µg/kg bolus followed by a 0.3 µg/kg infusion diluted in 250 ml of 5% dextrose solution</description>
    <arm_group_label>Arm 2: diltiazem group</arm_group_label>
    <other_name>Diltiazem group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylcystein</intervention_name>
    <description>Received 150 mg/kg acetylcystein diluted in 250 ml of 5% dextrose solution</description>
    <arm_group_label>Arm 3: acetylcystein group</arm_group_label>
    <other_name>Acetylcystein group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>diltiazem and acetylcystein</intervention_name>
    <description>Received a combination of drug :diltiazem and acetylcystein
bolus diltiazem 100 µg/kg followed by a 0.3 µg/kg infusion diluted in 125 ml of a 5% dextrose solution
150 mg/kg acetylcystein diluted in 125 ml of 5% dextrose solution</description>
    <arm_group_label>Arm 4: diltiazem and acetylcystein group</arm_group_label>
    <other_name>Combined diltiazem and acetylcystein drug group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age included between 60 and 80 years

        Exclusion Criteria:

          -  Age &lt; 60 or &gt; 80 years

          -  Pregnancy

          -  The allergy in used medicines (N-acétylcystéine, Diltiazem)

          -  Presence of a pathology valvulaire associated

          -  Urgency

          -  Unstable angor

          -  Bypass as a matter of urgency

          -  Recours peropératoire to a CEC

          -  FE &lt; 0,40

          -  BAV of the 2nd and 3rd not sailed degree

          -  fibrillation or flutter little finger.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annick Steib, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Strasbourg University Hospital, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Anaesthesiology</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 27, 2012</study_first_submitted>
  <study_first_submitted_qc>January 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2013</study_first_posted>
  <last_update_submitted>January 16, 2013</last_update_submitted>
  <last_update_submitted_qc>January 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ischaemia-reperfusion injury</keyword>
  <keyword>cardiac surgery</keyword>
  <keyword>oxidative stress markers</keyword>
  <keyword>troponin</keyword>
  <keyword>diltiazem</keyword>
  <keyword>acetylcystein</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Diltiazem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

